Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

531 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial.
Eastell R, Lang T, Boonen S, Cummings S, Delmas PD, Cauley JA, Horowitz Z, Kerzberg E, Bianchi G, Kendler D, Leung P, Man Z, Mesenbrink P, Eriksen EF, Black DM; HORIZON Pivotal Fracture Trial. Eastell R, et al. Among authors: delmas pd. Osteoporos Int. 2010 Jul;21(7):1277-85. doi: 10.1007/s00198-009-1077-9. Epub 2009 Oct 3. Osteoporos Int. 2010. PMID: 19802508 Free PMC article. Clinical Trial.
Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.
Eastell R, Black DM, Boonen S, Adami S, Felsenberg D, Lippuner K, Cummings SR, Delmas PD, Palermo L, Mesenbrink P, Cauley JA; HORIZON Pivotal Fracture Trial. Eastell R, et al. Among authors: delmas pd. J Clin Endocrinol Metab. 2009 Sep;94(9):3215-25. doi: 10.1210/jc.2008-2765. Epub 2009 Jun 30. J Clin Endocrinol Metab. 2009. PMID: 19567517 Free PMC article.
A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.
Reginster JY, Felsenberg D, Cooper C, Stakkestad JA, Miller PD, Kendler DL, Adami S, McClung MR, Bolognese MA, Civitelli R, Dumont E, Bonvoisin B, Recker RR, Delmas PD. Reginster JY, et al. Among authors: delmas pd. Osteoporos Int. 2006 Feb;17(2):159-66. doi: 10.1007/s00198-005-1957-6. Epub 2005 Jun 14. Osteoporos Int. 2006. PMID: 15959614 Review.
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR; HORIZON Pivotal Fracture Trial. Black DM, et al. Among authors: delmas pd. N Engl J Med. 2007 May 3;356(18):1809-22. doi: 10.1056/NEJMoa067312. N Engl J Med. 2007. PMID: 17476007 Free article. Clinical Trial.
Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure.
Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, García-Hernandez PA, Supronik J, Lewiecki EM, Ochoa L, Miller P, Hu H, Mesenbrink P, Hartl F, Gasser J, Eriksen EF. Recker RR, et al. Among authors: delmas pd. J Bone Miner Res. 2008 Jan;23(1):6-16. doi: 10.1359/jbmr.070906. J Bone Miner Res. 2008. PMID: 17892374 Free article. Clinical Trial.
Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.
Grbic JT, Landesberg R, Lin SQ, Mesenbrink P, Reid IR, Leung PC, Casas N, Recknor CP, Hua Y, Delmas PD, Eriksen EF; Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial Research Group. Grbic JT, et al. Among authors: delmas pd. J Am Dent Assoc. 2008 Jan;139(1):32-40. doi: 10.14219/jada.archive.2008.0017. J Am Dent Assoc. 2008. PMID: 18167382 Clinical Trial.
531 results